How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action.
Janssens R, Barbier L, Muller M, Cleemput I, Stoeckert I, Whichello C, Levitan B, Hammad TA, Girvalaki C, Ventura JJ, Bywall KS, Pinto CA, Schoefs E, Katz EG, Kihlbom U, Huys I.
Janssens R, et al. Among authors: whichello c.
Front Pharmacol. 2023 Aug 16;14:1192770. doi: 10.3389/fphar.2023.1192770. eCollection 2023.
Front Pharmacol. 2023.
PMID: 37663265
Free PMC article.